B
reast cancer is globally the most common type of cancer in women, 1 and for many years, it has been difficult to treat, leading to high mortality and morbidity rates. Due to recent advances in its diagnosis and treatment, survival rates have increased. 2 Between 1991 and 2006, the overall cancer death rate among women decreased by 12.3%. The reduction in breast and colorectal cancer rates accounted for 60% of the total decrease. 3 Treatment of breast cancer may include surgical treatment, chemotherapy, and radiation therapy. Approximately 80% of breast cancers concern estrogen receptor-positive tumors, 4 which can be treated with adjuvant endocrine therapy in accordance with recent clinical practice guidelines. 5 This adjuvant therapy comprises aromatase inhibitors (AI) or selective estrogen receptor modulators (SERM). For many years, tamoxifen (SERM) was the cornerstone of endocrine therapy, with a substantial body of evidence showing benefits on overall survival. 6 The third-generation AI have more recently become the standard of care in the management of both early and advanced hormone-responsive breast cancer in postmenopausal women. 7 Studies have shown that AIs instead of, or given sequentially to, tamoxifen have improved disease-free survival. 8 At present, the standard duration of postoperative adjuvant endocrine therapy is 10 years. 5 Although this adjuvant treatment provides a valuable addition to breast cancer therapy, it is not without side effects. [9] [10] [11] [12] [13] The most frequently reported unwanted side effects are arthralgia, myalgia, carpal tunnel syndrome, stiffness, and paresthesia. These are included in AI-induced musculoskeletal syndrome (AIMSS). 13 The exact mechanism of AI-related arthralgia is unclear, but it is believed to be related to estrogen deprivation. 14, 15 In large adjuvant trials involving AI, the incidence of musculoskeletal disorders was 20% to 47%. [16] [17] [18] For selective estrogen receptor modulators, joint and muscle pain as side effects are somewhat less important. 19 Musculoskeletal complaints are associated with an impaired quality of life 11 and may affect compliance. For up to 50% of patients, the intolerable concomitant side effects are a reason for not taking the adjuvant endocrine treatment as prescribed. 20 This includes both noncompliance and early discontinuation of adjuvant therapy. 20 Discontinuation rates within the first year can reach up to 20%. 21, 22 This is an important clinical issue because it has been shown that deviation from the prescribed endocrine treatment is associated with increased mortality in women with breast cancer. 20 It has also been reported that in general, in patients with breast cancer, muscle strength and muscle mass may decline during treatment. 23, 24 As the literature suggests that the adverse effects of adjuvant endocrine therapy are seen most predominantly in the hands, researchers have used grip strength as a representative parameter for musculoskeletal side effects. 11, 12 A cross-sectional study reports that patients receiving AI medication have decreased grip strength compared to normative data. 25 Dominant hand grip strength was also found to correlate inversely with endocrine therapy side effects. 26 The available evidence on changes in grip strength associated with adjuvant endocrine treatment, however, appears to be inconclusive, and at present the existing literature on the impact of treatment on grip strength has not been synthesized. Therefore, the purpose of this paper was to systematically and critically appraise the available scientific evidence concerning the effect of adjuvant endocrine treatment on grip strength in women who are being treated for breast cancer.
Methods
The recommendations for strengthening the reporting were followed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA statement). 27 The protocol of this systematic review detailing the review method was developed a priori following initial discussions among members of the research team.
Focused Question
In women who are being treated for breast cancer, what is the effect of adjuvant endocrine treatment on grip strength in comparison to treatment for breast cancer in which no (as yet) adjuvant endocrine treatment is used? 
Data Sources and Searches

Screening and Study Selection
The titles and abstracts of the studies obtained following the searches were independently screened by 2 reviewers (EvdW, DES) and were categorized as definitely eligible, definitely not eligible, or questionable. No attempt was made to blind the reviewers to the names of authors, institutions, or journals while making the assessment. If eligible aspects were present in the title, the paper was selected for further reading. If none of the eligible aspects were mentioned in the title, the abstract was read in detail to screen for suitability. Papers that could potentially meet the inclusion criteria were obtained and read in detail by the 2 reviewers (EvdW, DES). Disagreements in the screening and selection process concerning eligibility were resolved by consensus or, if disagreement persisted, by arbitration through a third reviewer (CB). The papers that fulfilled all of the inclusion criteria were processed for data extraction.
Inclusion criteria were the following: grip strength measurement, in (randomized) controlled clinical trials or observational studies, including women who have been or are being treated for breast cancer and are starting on adjuvant endocrine treatment. No language restrictions were imposed.
Exclusion criteria were the following: studies involving women with endocrine treatment but without breast cancer and women being treated for breast cancer with adjuvant endocrine treatment but also participating in physical training. Additionally, abstracts, letters, case reports, and reviews were not included in the selection.
Data Extraction and Quality Assessment
The data from the papers that met the eligibility criteria were processed for further analysis. Characteristics of the patient sample, intervention, comparison, and relevant outcomes were extracted independently by 2 reviewers (EvdW, DES) using a specially designed data extraction form. The means, standard deviations, standard error, 95% confidence intervals, and reductions in terms of percentage were extracted if provided. For studies with multiple evaluation time points, the data from the baseline and final evaluation were used. For the papers that provided insufficient/incomplete data to be included in the analysis, the first or corresponding authors were contacted to verify whether they could provide additional data. When more publications on the same study population were published, either the data from the most recent publication were extracted or the study with the highest number of participants was chosen as representative for data analysis and calculations. This was implemented to avoid including the same participants reported in different papers more than once. To warrant a precise estimate, any data approximation in figures was avoided.
Two reviewers (EvdW, DES) independently scored the individual methodological qualities of the included studies using the checklist from the STROBE-statement of items that should be reported in observational studies using routinely collected health data and extended in the RECORD-statement as retrieved from the Equator Network. 28 For the quality assessment score, individual items with a positive rating were summed to obtain an overall percentage score. 23 The estimated risk of bias was interpreted as follows: 75% to 100% of the criteria met = low estimated risk of bias, 50% to 74% = moderate risk, 25% to 49% = substantial risk, and <25% indicated a high estimated risk of bias. 29 The agreement between reviewers on positive quality scores was evaluated using Cohen's kappa statistic and was interpreted as "almost perfect" (kappa>.8), "substantial" (kappa>.6), and "moderate" (kappa>.4). 30 Disagreements were resolved by consensus.
To assess heterogeneity among the studies, the following factors were considered:
• Study design and evaluation period • Measurement outcome tool
• Study groups (eg, based on type of medication)
• Industry funding
Data Synthesis and Analysis
The collective data and the statistical analysis of all included studies were summarized and presented in a descriptive manner. P values <.05 were accepted as statistically significant. If possible Search terms used for MEDLINE-PubMed. The search strategy was customized for Cochrane-CENTRAL, EMBASE, CINAHL, and PEDro according to the criteria of the database being searched. The following strategy was used in the search: {<breast cancer> AND <medication> AND <grip strength>}.
Figure 2.
Flow Chart of the Search and Selection Process and where appropriate, the percentage change in grip strength was calculated (if not provided) for each individual experiment based on the baseline and end-point data. If data were reported for left and right arms separately, the data were also pooled. It was determined a priori to perform sub-analyses if possible for type of medication (AI or SERM), differences between left and right arms, and symptomatic compared to nonsymptomatic patients.
Grading the "Body of Evidence"
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to rank the evidence. 31 Two reviewers (DES, GAW) rated the quality of the evidence and the strength and direction of the recommendations 32 according to the following aspects: risk of bias, consistency of results, directness of evidence, precision and publication bias, and magnitude of the effect.
Results
Search and Selection Results
The screening of 716 unique titles and abstracts of the search outputs from the PubMed-MEDLINE, Cochrane-CEN-TRAL, EMBASE, CINAHL, and PEDRO databases resulted in 22 potentially eligible papers (Fig. 2 ).
Based on a detailed reading of the full texts, 15 papers were rejected. The reasons for rejection were that they included 10 conference/symposium abstracts, 26,33-41 1 study included patients not starting on adjuvant endocrine therapy, 42 1 summary of a symposium presentation, 43 1 editorial, 44 1 that did not address grip strength in relation to concomitant medication, 45 and 1 review. 7 Hand searching of the reference lists of the eligible papers did not reveal additional papers. Subsequently, 7 eligible publications were included in this review.
Description of the included studies. The characteristics of the included studies exhibit considerable heterogeneity, detailed information on which is provided in eAppendixes 1 and 2 (available at https://academic. oup.com/ptj). The most prominent differences are the instruments to measure grip strength and the units in which the outcome is presented. Three prospective observational cohort studies [46] [47] [48] 13 assessed grip strength in a large cohort at baseline and after 12 months and differentiate between patients receiving tamoxifen or AI. In all but 1 included study, 50 the participants were postmenopausal women with breast cancer. The reported mean age varied between 58 and 68 years.
Quality Assessment
A summary of the quality assessment criteria for observational studies is presented in eAppendix 3 (available at https://academic.oup.com/ptj). Based on adherence to these criteria, which ranged from 81% to 92%, the estimated potential risk of bias is considered to be low for the 7 included studies. The most important item missing in all but 1 study 13 is the justification of the study sample size. There was substantial agreement in the independent evaluation of study quality between reviewers (κ = .62). Formal testing of publication bias could not be performed. However, because 4 of the 8 included studies originated from the same research group, publication bias may be a concern.
Descriptive Analyses
Due to considerable heterogeneity in outcome units, it was impossible to combine the mean results of the included studies into a formal meta-analysis (eAppendix 2, available at https://academic.oup.com/ptj). Therefore, as a summary, a descriptive data presentation of all studies is provided (Tab. 1).
Six studies reported on the changes in grip strength in patients starting on AI medication. 11, 13, 46, 47, 49, 50 Two of these studies 46, 47 share the same patient sample, and the 1 with the largest sample size was used for this review 47 (Tabs. 2 and 3). Four studies 11, 13, 47, 50 reported that they observed a decrease in grip strength during AI treatment compared to baseline. One included study was a follow-up study of Lintermans et al 47 and reported that the average grip strength of patients on AI shows a nonsignificant decrease from 6 months to 24 months (P = .19) 48 (Appendix 2, available at https://academic.oup. com/ptj). Table 2 presents the effect of adjuvant endocrine therapy as percent reduction in grip strength in studies with a follow-up of 6 or 12 months. These varied for left and right hand combined from a nonsignificant reduction of 0.1% to a reduction 9.7%, which was significant for both the left and right hand.
Gallicchio et al 50 reported that the change from baseline to end in mean grip strength changed significantly in their group of white participants both in the dominant (P = .004) as well as the nondominant hand (P = .01, Tab. 2). Lintermans et al 47 reported that in patients on AI, there is a tendency for a difference in grip strength reduction between right (-11.4%) and left hands (-8.0%), although no statistical analysis is provided (Tab. 2). A report on the same patient sample and investigating confounding factors found an association between AI-induced loss of grip strength and extremes in BMI (Lintermans et al 47 ) . A regression analysis suggested that grip strength decreased more in participants with an extremely low or high BMI.
With a total study population of 52 patients, Singer et al 11 performed a sub-analysis on changes in grip strength between patients with joint and muscle symptoms (-2.9 kg) and without symptoms (-1.3 kg). They reported a trend towards a greater decrease in patients with symptoms; this was not significant (P = .06). Lintermans et al, 13 however, with a study population of 188 patients, did find a significantly larger decrease in grip strength in patients experiencing AI-induced pain compared with patients on AI without new or worsened pain (difference = -2.5 kPa, P = .0002) (Tab. 3).
Lintermans et al 13, 47 distinguished changes in grip strength relative to the medication that the patients are receiving, namely tamoxifen or AI. They observed that a decrease in grip strength is more evident in AI than in tamoxifen users. The percent change in grip strength in studies with a follow-up of 6 or 12 months is presented in Table  2 . These varied for left and right hand combined from a nonsignificant reduction of 1.4% to a reduction of 2.2%, for which no data on statistical significance were provided.
Grading the "Body of Evidence" Table 4 shows a summary of the various factors used to rate the quality of evidence and the strength and direction of the recommendations. For tamoxifen, the reported outcomes were consistent, generalizable, and rather precise. Publication bias could be a concern, however-and considering that the estimated risk of bias was low-the strength of the recommendation was considered to be high. For AI, the outcomes were generalizable, rather precise but inconsistent. Publication bias could be a concern, and with a low to moderate estimated risk of bias, the strength of the recommendation was considered moderate. The magnitude of the effect (if present) in relation to clinical relevance was considered to be small.
Discussion
The present review systematically evaluated the effects of adjuvant endocrine treatment on hand grip strength, and the results show that in patients with breast cancer receiving adjuvant endocrine treatment, there is moderately strong evidence that a reduction in grip strength may be observed. There is a difference in reduction in grip strength between patients receiving AI and those receiving tamoxifen. For patients receiving tamoxifen, the underlying evidence is estimated to be strong. This was reported to be not significant in the underlying included papers. The strength of the underlying evidence for patients receiving AI was found to be moderate. The results of the included individual studies that contributed to this latter outcome are inconclusive, but all show a numerical decrease. Some report this to be a significant reduction, whereas others do not (Tab. 1). If all other issues around treatment of patients being treated for breast cancer would be equal, these results appear to recommend against the use of AI and to favor tamoxifen.
In addition to the use of tamoxifen and AI, other factors could result in a decrease in grip strength. The side effects common to both agents are largely predictable consequences of estrogen Gallicchio et al 50 Lintermans et al 13 Lintermans et al 47 Lintermans et al 47 Lintermans et al 48 Lintermans et al 13 Singer et al 11 Swenson et al 49 Risk 51 In all but 1 of the included studies, patients were reported to be postmenopausal women. Grip strength deficits may also arise from tumorproduced inflammatory intermediates that are catabolic, resulting in muscle wasting (cachexia). Surgical interventions may also damage muscle groups and peripheral nerves, leading to a loss of strength. Radiation and chemotherapy (especially the vinca alkaloids, taxanes, and platinum agents) can reduce strength by damaging muscle or peripheral nerve tissue. 52 The major risk factors for a reduction in muscle strength on the affected side of patients with breast cancer are axillary lymph node dissection and concurrent radiation and/or chemotherapy. 23, 53 None of the included studies report on the relationship between the cancer-affected side and hand grip strength. However, 3 of the included studies reported a bilateral effect on grip strength, 47, 48, 50 which suggests general impairment rather than a consequence of axillary operation and/or radiotherapy. One study 50 reported that patients in 1 subgroup of the study sample were more likely to have undergone a bilateral mastectomy, which in turn would then have had impact on both hands. Finally, pain, fear, and fatigue can also lead to inactivity, which in turn causes further loss of grip strength. 52 Based on the normative dataset of a healthy adult Swiss population, 54 a significant difference between dominant and nondominant grip strength is apparent (mean difference = 1.15kg, 95% CI, ranging from 0.93 to 1.36 kg).
In the normative dataset, the dominant hand was the right hand in 88.3% of the cases. One included study in this review 47 reported that there is a tendency (P value not provided) for the decrease in grip strength (-11.4%) in the right hand (interpreted as dominant) to be greater than the decrease (-8%) in the left hand (interpreted as nondominant). Gallicchio et al 50 present data on the dominant and nondominant hand and observed at 12 months a significant reduction in grip strength of both hands. These reductions totaled 3.8 psi in the dominant hand and 3.2 psi in the nondominant hand in their Caucasian subgroup.
Of the cohort studies, the studies by Morales et al 46 and Lintermans et al 13, 47, 48 show a significant decrease in grip strength over time. These researchers used a modified sphygmomanometer (Albert Waeschle Ltd, Dorset, UK). In contrast, 3 other cohort studies evaluated grip strength using the Jamar hydraulic hand dynamometer (Performance Health, Warrenville, IL). This measuring device has been shown to be the most accurate and reproducible, 55 with published normal values across age ranges. 56 Swenson et al 49 suggest that the differences in instrumentation and measurement techniques may explain the differences in findings. Squeezing a balloon of a modified sphygmomanometer to measure maximal force may have been a more sensitive test than the handheld dynamometer. 49 However, it actually measures grip pressure, which introduces variation in the results due to individuals having different hand surface areas. 7 In an abstract describing a 3-and 6-month evaluation after initiating AI, Crew et al 39 report a numerical increase in grip strength (n = 85, P = .26) assessing hand grip strength with a Martin dynamometer (vigorimeter). Therefore, selecting the best outcome measure requires careful consideration of issues beyond the usual questions about reliability and validity. The ultimate value of a clinical trial or outcome study will be directly tied to how well a change over time can best be identified. 57 It is essential to consider the magnitude of the observed differences, as small differences are not likely to be clinically relevant. 45, 58 The interpretation of the results obtained in this review is complicated due to the varying measurement techniques and varying units in which outcomes were expressed. A study by Nitschke et al 59 evaluated the test-retest reliability of the maximum grip strength of 32 healthy women and 10 women with disability. The measurement variation between tests was ±5.7 kg for the healthy women and ±5.9 kg for the women with disability. They therefore proposed a minimum change of 6 kg to be relevant. Similarly, it has been stated that a change in force of at least 61 Newton (N) is needed between 2 sessions to be 95% confident that a real change has occurred. 60 This is in agreement with the more recently reported minimum clinically important difference in grip strength, which was 6.5 kg. 61 The only study that expressed the outcomes in kg 11 does not exceed these thresholds, which suggests that the observed effect most likely is not clinically relevant. It is difficult to judge the studies that presented their data as kPa or psi. However, when looking at the data in relation to those observed with the outcome presented in kilograms, 11 the changes appear to be on the edge of being clinically relevant.
What is striking is that the mean baseline values presented by Singer et al 11 exceed the normative data 62 by almost 50%. The impact of this on the outcome cannot be established in this review. This could be the result of an incorrect presentation of the unit of measurement (eg, lb instead of kg). Also worth noting is that Gallicchio et al 50 presented their data as psi, although the scale readout of the Jamar dynamometer presents force in either pounds or kilograms. Upon our request both these authors did not elucidate these discrepancies.
The included cohort studies all lack a control group of patients with breast cancer not receiving adjuvant endocrine therapy. 11 Age-related decline in muscle strength is among the most important factors in the aging process. 63 Stenholm et al 64 reported that the annual decrease in grip strength in women prior to the age of 45 years was approximately 2N. After the age of 80 years, this was approximately 4N per year. Relative to normative data 54, 65 this would be approximately a 0.6% (<45 years) and 2% (≥80 years) grip strength reduction annually. None of the included studies in this review mention that this natural decrease is relevant to their outcomes, nor do they correct for this. One symposium abstract identified in the search 41 presented a 3-month evaluation that did include a control group and described the early features of AI therapy. In those on AI, the development of arthralgia was not shown to be associated with change in grip strength. The group receiving upfront AI (n = 34) showed a change in grip strength of +0.2% as opposed to +1.2% in the control group (n = 8, P = not significant). Mean percentage change in grip strength in the group on tamoxifen (n = 22) was +4.5% and not significantly different from the other groups.
The long-term effects of profound estrogen suppression in patients with breast cancer taking AI are unknown. 7 Until interventions are identified, patients who experience severe adverse effects should be reassured that the clinical benefit of AI compared with tamoxifen is modest, thus, for some, changing therapy may be a solution. 18 Then again, studies have shown that for patients who had been receiving AI for at least 6 months, the associated effect on grip strength was minor and nonsignificant. 48, 66 Singer et al 11 conclude that if women who develop pain have worse physical function at baseline, this is a potentially modifiable risk factor for AIMSS. They speculate that there may be a treatment benefit obtained by improving physical function prior to starting AI treatment. Oncologists prescribing AI can use this proposal to counsel women prior to the initiation of these drugs, although further research is needed to verify the clinical significance of such an intervention. Additionally, there may be a specific subgroup for whom low muscle mass is an important cause of their symptoms. It would be beneficial for these patients to be identified because they are the most likely to benefit from therapies that increase muscle mass. 67 Finally, a nonlinear relationship between BMI and AI-induced loss of grip strength was observed by Lintermans et al, 47 which suggests an underlying biological process. A high BMI as 
Limitations
Systematic reviews are considered the gold standard for summarizing and appraising the existing evidence by systematically and transparently identifying all relevant studies following a strict protocol. Systematic reviews can provide evidence as part of the clinical decision process. 70 However, several limitations were identified during the review process. Only 2 included papers 49, 50 transparently reported the mean outcomes at the end of the study. Five other cohort studies only reported data with respect to alterations. This precluded a meta-analysis. A potential weakness of the present review is that the selected studies lacked data on interobserver and intraobserver variability in grip strength recordings. An omission of all included studies is that only women who were receiving adjuvant AI therapy were included; they thus did not capture women who discontinued therapy early as a result of adverse effects. This might have consequences for the mean outcome in grip strength.
Unanswered Questions and Future Research
The majority of the included studies had a duration of 6 to 12 months. One study reported a further nonsignificant decrease in grip strength after 6 months up to 24 months. 48 The study noted that this is in contrast to what has been suggested, namely that arthralgia may be self-limiting with a reduction of symptoms over time. 48 As AI are now recommended in the adjuvant treatment setting, many women with breast cancer will be exposed to several and possibly many years of treatment (up to 5 years). 5 It is therefore interesting to evaluate to what extent long-term use of AI affects grip strength.
A better sense of the adequacy of grip strength might be gained by a formal meta-analysis. Future studies should use validated measurement tools, report the means and standard deviations, and also select a common unit of outcome.
Conclusion
Based on studies with a low estimated risk of bias, there is inconclusive evidence that grip strength decreases in women being treated for breast cancer and receiving AI. All included papers report a numerical decrease that is only significant in some studies. The results appear to be related to the measurement device used. Furthermore, the clinical relevance of the observed differences is questionable. There was no consistent difference in grip strength between patients with and without muscle or joint symptoms. In tamoxifen users, grip strength did not change significantly.
Implications for practice. Grip strength may be associated with musculoskeletal symptoms in patients with breast cancer receiving adjuvant therapy with AI. Furthermore, given the inconclusive results of the included studies and the estimated small clinical relevance, change of grip strength appears to be an unsuitable parameter for assessing AIMSS in patients being treated for breast cancer. In addition, for patients with breast cancer receiving tamoxifen, the lack of a significant change in grip strength indicates that it is likely not associated with musculoskeletal side effects. 
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